RxDoctor Payments Data

Maria-Lucia Deausen

Nurse Practitioner · Bethesda, MDNPI 1134330715

Payments from drug & device makers

$1,766in general payments, 2019–2025

Across 93 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$698
  • Lilly USA, LLC$327
  • AstraZeneca$144
  • Abbott$124
  • Smith+Nephew$68
  • Boehringer Ingelheim$64
  • plus $341 from 10 others

What the payments were for

  • Food & beverage$1,766100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,766 in reported general payments places this provider in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$19,279
Medicare patients
126
Services billed
131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$37,314
RybelsusSemaglutide23$36,356
Breo ElliptaFluticasone/Vilanterol14$16,894
EliquisApixaban14$15,260
Rosuvastatin Calcium69$1,741
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide16$757
Montelukast Sodium45$669
Metoprolol Succinate27$627
Atorvastatin Calcium52$607
Famotidine34$582
Albuterol Sulfate HfaAlbuterol Sulfate17$566
Losartan Potassium55$395
Levothyroxine Sodium28$381
Amlodipine Besylate77$379
Olmesartan Medoxomil12$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$698$73,67041 claims
PfizerEliquis$19$15,26014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →